The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
Not a dead parrot. Webinar , 1 July, 15-17 CET. Register here if you want to pose questions, otherwise live on YouTube here . Recording ... -
It was a real pleasure yesterday to share some reflections on the European experience with the Digital Markets Act across the Atlantic. You ... -
ArsTechnica, here . Picture chosen by ArsTechnica for the article. This picture suddenly recalled a Ted Talk I gave 12 years ago touching... -
Chamber of Progress, here.
-
IGF 2025, here.
-
L. Khan, S. Levine, S. Nguyen, here.
-
Open Future, here.
-
L. Lowe, here and here . And the EC has once again confirmed that it won't, here and here.